ProfileGDS5678 / 1452492_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 84% 84% 83% 83% 88% 87% 85% 86% 82% 82% 81% 80% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.1263484
GSM967853U87-EV human glioblastoma xenograft - Control 26.3416284
GSM967854U87-EV human glioblastoma xenograft - Control 36.1924484
GSM967855U87-EV human glioblastoma xenograft - Control 46.185683
GSM967856U87-EV human glioblastoma xenograft - Control 56.1175583
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5445788
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4596387
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.2746685
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4556286
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9666582
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9932982
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7909881
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7089380
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2000784